DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

Ejemplares similares

• Inclusive $K^{*0}$(890) and $\overline{K}$$^{*0}$(890) production on beryllium by $K^{-}$ and $\pi^{-}$ at 175 GeV
  por: Bailey, R, et al.
  Publicado: (1984)
• Inclusive K%+(890), K%+(1430) and $\overline{K}$%-(890) production in K+p interactions at 32 GeV/c
  por: Ajinenko, I, et al.
  Publicado: (1984)
• K%0(890) polarization measurements in the hypercharge exchange reaction pi-p --> K%0(890)LAMBDA0/SIGMA0 at 10 GeV/c
  por: Armstrong, T A, et al.
  Publicado: (1979)
• K%0(890) polarization measurements in the hypercharge exchange reaction pi-p --> K%0(890)LAMBDA0/SIGMA0 at 10 GeV/c
  por: Evangelista, C, et al.
  Publicado: (1980)
• $k^{*0}$(890) polarization measurements in the hypercharge exchange reaction $\pi^{-}p \to k^{*0}(890)\Lambda^{0}/\Sigma^{0}$ at 10 GeV/c
  por: Picciarelli, V, et al.
  Publicado: (1979)